Spectrum Pharmaceuticals has announced the results of a Phase II marker lesion study of EOquin by intravesical instillation in superficial bladder cancer.

A total of 46 patients with multiple lesions of superficial bladder cancer were entered into this multicenter study. After surgical removal of all except one "marker" lesion, patients received six weekly instillations of EOquin into the bladder. Complete disappearance of the tumor was histologically documented in 30 patients. The data indicates that EOquin by intravesical instillation demonstrates significant anti-tumor activity in superficial bladder cancer and is well tolerated in patients.

EOquin is the trade name for apaziquone, a potential anticancer agent, formulated for administration directly into the urinary bladder. It is activated by certain enzymes present in higher amounts in cancer cells than in normal cells.